Document Detail


Female hormones affect symptom severity in obsessive-compulsive disorder.
MedLine Citation:
PMID:  16528139     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There is circumstantial evidence that reproductive events can influence symptom severity of obsessive-compulsive disorder (OCD). We sent self-report questionnaires to 350 female outpatients with OCD to examine the relationship between the menstrual cycle, pregnancy, menopause, hormonal contraceptives, selective serotonin reuptake inhibitors and symptom severity of OCD. Yale-Brown Obsessive-Compulsive Scale scores were used at three serial time points during the menstrual cycle to assess symptom severity. One hundred and one out of 350 questionnaires (29%) were returned and completed. Forty-nine patients reported an exacerbation of OCD symptoms during the premenstrual period, nine during the menopause and 17 patients during pregnancy, whereas 11 patients mentioned improvement of OCD symptoms during pregnancy. Premenstrual dysphoric disorder could only partly explain a premenstrual exacerbation of OCD symptoms. Exacerbation of OCD could be related to reproductive events in a considerable number of patients, especially the premenstrum. Because reproductive cycle events influence the symptom severity of OCD, the menstrual cycle should be taken into account when assessing the severity of OCD symptoms during pharmacological studies.
Authors:
Nienke C C Vulink; Damiaan Denys; Léonie Bus; Herman G M Westenberg
Related Documents :
1427629 - Hysteroscopic assessment of midsecretory-phase endometrium, with special reference to t...
8147239 - Follicular development and its control.
14664409 - Effect of short follicular phase with follicular maturity on conception outcome.
8988529 - Reproductive toxicity of ovulation induction.
2351709 - A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone suppo...
2324259 - Post-operative artificial insemination--does it improve gift outcome?
17707049 - Prenatal magnetic resonance imaging demonstrates linear growth of the human fetal kidne...
14770389 - Relationship between monitoring parameters and perinatal outcome in severe, early intra...
6148629 - Coitus during pregnancy: is it safe?
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International clinical psychopharmacology     Volume:  21     ISSN:  0268-1315     ISO Abbreviation:  Int Clin Psychopharmacol     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-03-10     Completed Date:  2006-10-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8609061     Medline TA:  Int Clin Psychopharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  171-5     Citation Subset:  IM    
Affiliation:
The Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands. n.c.vulink@azu.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antidepressive Agents / pharmacology,  therapeutic use
Antipsychotic Agents / pharmacology,  therapeutic use
Clomipramine / therapeutic use
Contraceptives, Oral, Hormonal / pharmacology,  therapeutic use
Depression, Postpartum / physiopathology
Drug Therapy, Combination
Female
Gonadal Steroid Hormones / physiology*
Humans
Menopause / physiology
Menstrual Cycle / physiology
Middle Aged
Obsessive-Compulsive Disorder / pathology,  physiopathology*
Pregnancy
Premenstrual Syndrome / drug therapy,  physiopathology
Questionnaires*
Recurrence
Reproducibility of Results
Serotonin Uptake Inhibitors / therapeutic use
Severity of Illness Index
Withholding Treatment
Chemical
Reg. No./Substance:
0/Antidepressive Agents; 0/Antipsychotic Agents; 0/Contraceptives, Oral, Hormonal; 0/Gonadal Steroid Hormones; 0/Serotonin Uptake Inhibitors; 303-49-1/Clomipramine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, effica...
Next Document:  An open-label study of escitalopram in body dysmorphic disorder.